FluxMPS™ Minimum Essential Medium (MEM), High Glucose w/o L-Glutamine, Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ Minimum Essential Medium (MEM), High Glucose w/o L-Glutamine, Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ Minimum Essential Medium (MEM), High Glucose w/o L-Glutamine, Sodium Bicarbonate, Phenol Red: 1X Liquid is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• High glucose (4.5 g/L) base formulated without L-glutamine, sodium bicarbonate, or phenol red — supplement each per your protocol
• Quadruple-stage filtration train: 0.1 µm (Prefiltration I & II) + 0.04 µm (Final filtration I & II), four validated passes per lot
• Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85> BET), tested per manufacturing batch
• pH 7.4 (USP <791>); osmolality reported on the Certificate of Analysis
• Prepared with Type 1 water (18.2 MΩ·cm, ASTM D1193 / ISO 3696) for low trace-metal and organic-carbon background
• Manufactured under an ISO 13485:2016 quality management system; final QC at Diagnocine, Totowa NJ
• Bicarbonate-free and phenol-red-free formulation — CO₂ buffering is not required; add HEPES if extended non-incubator handling is needed
• Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized organisms (0.2–0.3 µm), subvisible debris, and endotoxin variability that accumulate inside microchannels — corrupting biosensor readings, stressing primary cultures, and shortening device lifetimes. FluxMPS™ addresses these failure modes with a validated four-stage filtration train.

Quadruple-stage filtration system

FluxMPS™ Minimum Essential Medium (MEM), High Glucose w/o L-Glutamine, Sodium Bicarbonate, Phenol Red: 1X Liquid is processed through a validated four-stage filtration sequence reaching a 0.04 µm final cut-off — engineered to retain mycoplasma-sized organisms and subvisible particulates that a standard 0.22 µm filter cannot exclude.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris, and protein aggregates; protects the first 0.04 µm final filter cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains fine particulates and organisms in the mycoplasma size range (0.2–0.3 µm) that pass a standard 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter stage, protecting the second 0.04 µm final filter cartridge from residual particulate load.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter prior to ISO Class 5 aseptic fill & finish.

Designed for next-generation cell culture platforms

FluxMPS™ Minimum Essential Medium (MEM), High Glucose w/o L-Glutamine, Sodium Bicarbonate, Phenol Red: 1X Liquid is validated for organ-on-a-chip, cancer biology, metabolic research, live-cell imaging, and vascular cell models where particulate contamination and endotoxin variation are unacceptable.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra-filtered variant is available for automated bioreactor and robotic perfusion systems requiring the highest particulate exclusion.

• Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
• Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm grade.

Lot-release quality parameters

Every production batch of FluxMPS™ Minimum Essential Medium (MEM), High Glucose w/o L-Glutamine, Sodium Bicarbonate, Phenol Red: 1X Liquid undergoes the complete quality-release battery below before shipment.

Full composition (mg/L)

Complete formulation with CAS numbers, reproduced from manufacturer specification. Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

Manufactured under ISO 13485:2016 QMS with final packaging, testing, and customization at Diagnocine Precision in Totowa, New Jersey, USA.

How DCP-MEMG-QBRN1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered MEM High Glucose alternatives.

Comparison figures from published supplier specifications, accessed 2 September 2026. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ Minimum Essential Medium (MEM), High Glucose w/o L-Glutamine, Sodium Bicarbonate, Phenol Red: 1X Liquid and Microfluidics Suitable cell culture media.

Supporting literature

Peer-reviewed publications supporting Microfluidics Suitable ultra-filtered media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Eagle H (1959). Amino acid metabolism in mammalian cell cultures. Science, 130(3373), 432–437. doi:10.1126/science.130.3373.432
4. Warburg O (1956). On the origin of cancer cells. Science, 123(3191), 309–314. doi:10.1126/science.123.3191.309
5. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
6. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
7. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
8. Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539
9. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175